Dapagliflozin for advanced heart failure patients waiting for transplant
Part of Heart & circulation clinical trials.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 to 85 years old
- Severe heart failure symptoms (NYHA class III or IV) – meaning shortness of breath or fatigue even with minimal activity or at rest
- Heart's pumping strength (LVEF) is 35% or less
- Already on standard heart failure treatments, including dapagliflozin, at the highest tolerated doses
- On the waiting list for a heart transplant (or on the path to be listed), with no expected transplant in the next 6 months
- No current use of a heart pump (VAD), no dependence on IV heart medicines, and no recent hospital stay for worsening heart failure in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests whether a medicine called dapagliflozin can improve heart function in people hospitalized with acute heart failure. It may help the heart pump more efficiently and improve recovery.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.